SecBot SecBot
8-K ·Filed Apr 7, 2026

GTBP

GT Biopharma, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001493152-26-015413
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor for future clinical trial results, but note that this is an early-stage study with a relatively small funding commitment. The company remains in pre-revenue development stage.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.4130
T+0 close · Apr 7, 2026 · via day close
Latest settled
+14.24%
T+60 · $0.4718
Vs SPY
+0.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $0.4130entry
  2. T+1 · 7mo ago −1.94%α −4.48% · $0.4050
  3. T+5 · 7mo ago −5.81%α −11.14% · $0.3890
  4. T+20 · 7mo ago −7.26%α −17.04% · $0.3830
  5. T+60 · 5mo ago +14.24%α +0.97% · $0.4718
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to sponsor a phase 1a/1b clinical trial of its drug candidate GTB-5550 for advanced solid tumors. The company will fund up to $3.8 million over three years for the study, which remains in the early research phase.

Key Financial Metrics

Deal Value
$3.8M

Key Facts

  • GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota
  • The agreement supports a phase 1a/1b clinical trial of GTB-5550 for advanced solid tumors
  • GT Biopharma will fund up to $3.8 million over three years for the study
  • The trial is sponsored by the University of Minnesota, not GT Biopharma
  • The drug candidate GTB-5550 is in early-stage clinical development

Financial Impact

Up to $3.8 million over three years

cash flowR&D expenses

Risk Factors

  • Clinical trial may not demonstrate efficacy or safety
  • High risk associated with early-stage drug development
  • Limited financial resources for drug development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-015413
Document: form8-k.htm0001493152-26-015413
Document: 0001493152-26-015413-index-headers.html0001493152-26-015413
Document: 0001493152-26-015413-index.html0001493152-26-015413
Document: 0001493152-26-015413.txt0001493152-26-015413

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026